Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Closes $2.5M Private Placement

Premium

Rosetta Genomics this week announced that it has entered into a definitive agreement to sell securities to institutional investors in a private placement for aggregate gross proceeds of about $2.5 million.

Specifically, Rosetta will sell 2.5 million ordinary shares at a price of $1.00 per share, and give the purchasers warrants to buy up to 1.25 million ordinary shares at an exercise price of $1.30 per share and warrants to purchase up to 625,000 ordinary shares at an exercise price of $0.01 per share.

Rosetta said it will use the proceeds of the private placement for working capital purposes.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.